Clinical Trial Details
| Trial ID: | L0054 |
| Source ID: | NCT03910361 |
| Associated Drug: | Evoglitin |
| Title: | Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases |
| Acronym: | -- |
| Status: | Completed |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Type2 Diabetes|Non-Alcoholic Fatty Liver Disease |
| Interventions: | Drug: Evogliptin|Drug: Pioglitazone |
| Outcome Measures: | Changes from baseline intrahepatic fat (%) |
| Sponsor/Collaborators: | Dong-A ST Co., Ltd. |
| Gender: | All |
| Age: | 19 Years to 70 Years ?? (Adult, Older Adult) |
| Phases: | Phase 4 |
| Enrollment: | 51 |
| Study Type: | Interventional |
| Study Designs: | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment |
| Start Date: | April 12, 2019 |
| Completion Date: | July 2, 2020 |
| Results First Posted: | -- |
| Last Update Posted: | April 29, 2021 |
| Locations: | Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of |
| URL: | https://ClinicalTrials.gov/show/NCT03910361 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D405 | Evoglitin | Chemical drug | -- | DPP-4 inhibitor | -- | Under clinical trials | Details |
| D128 | Evogliptin | Chemical drug | DB12625 | DPP4 inhibitor | -- | Under clinical trials | Details |
| D275 | Pioglitazone | Chemical drug | DB01132 | PPARG agonist | Improve insulin resistance | Advanced in clinical trials | Details |